Antengene unveils three pipeline programs at AACR 2026 as AnTenGager platform expands beyond UCB deal
Can Kailera become the next major GLP-1 challenger after pricing one of biotech’s biggest IPOs in years?
Read More Healthcare Industry News Humacyte begins phase 2 Humacyl vascular trauma trial Humacyl vascular trauma trial : Humacyte, a regenerative medical technology company, has started a phase 2 clinical trial… bypharmanewsdailyNovember 10, 2018
